Principal Investigator
James Hoffman
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20160508
National Clinical Trials Identifier
NCT02791230
Clinical Trial Summary
Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy
Phase
Phase 3
Funding Agency/Sponsor
Industrial
Disease
Myeloma
Enrollment Eligibility
Inclusion Criteria:
Cohort A: Completion of 30 months of study treatment on Pfizer Protocol B3461028
Cohort B: Patients in specific countries diagnosed with ATTR-CM who did not previously
participate in Pfizer Study B3461028
Exclusion Criteria:
-Liver and/or heart transplant, or implanted cardiac mechanical assist device